Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66161-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- BMI1 antibody
- Antibody type
- Monoclonal
- Description
- KD/KO validated BMI1 antibody (Cat. #66161-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, mouse, monkey and has been validated for the following applications: IF, IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Simian
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 2E10A11
- Vial size
- 20ul, 150ul
Submitted references EPS8 supports pancreatic cancer growth by inhibiting BMI1 mediated proteasomal degradation of ALDH7A1.
Identification of a mesenchymal-related signature associated with clinical prognosis in glioma.
Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.
Inhibition of BMI1 induces autophagy-mediated necroptosis.
Tan M, Meng J, Sun X, Fu X, Wang R
Experimental cell research 2021 Oct 1;407(1):112782
Experimental cell research 2021 Oct 1;407(1):112782
Identification of a mesenchymal-related signature associated with clinical prognosis in glioma.
Zhang Z, Chen J, Huo X, Zong G, Huang K, Cheng M, Sun L, Yue X, Bian E, Zhao B
Aging 2021 Apr 19;13(9):12431-12455
Aging 2021 Apr 19;13(9):12431-12455
Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.
Qiu GZ, Mao XY, Ma Y, Gao XC, Wang Z, Jin MZ, Sun W, Zou YX, Lin J, Fu HL, Jin WL
Cancer science 2018 Jul;109(7):2199-2210
Cancer science 2018 Jul;109(7):2199-2210
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.
Dey A, Xiong X, Crim A, Dwivedi SKD, Mustafi SB, Mukherjee P, Cao L, Sydorenko N, Baiazitov R, Moon YC, Dumble M, Davis T, Bhattacharya R
Molecular cancer therapeutics 2018 Jan;17(1):39-49
Molecular cancer therapeutics 2018 Jan;17(1):39-49
Inhibition of BMI1 induces autophagy-mediated necroptosis.
Dey A, Mustafi SB, Saha S, Kumar Dhar Dwivedi S, Mukherjee P, Bhattacharya R
Autophagy 2016;12(4):659-70
Autophagy 2016;12(4):659-70
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- U-937 cells were subjected to SDS PAGE followed by western blot with 66161-1-Ig( BMI1 Antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The BMI1 antibody from Proteintech is a mouse monoclonal antibody to a recombinant protein of human BMI1. This antibody recognizes human, mouse antigen. The BMI1 antibody has been validated for the following applications: ELISA, WB, IHC, IF analysis.
